Results 181 to 190 of about 1,925 (192)

Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024

Influenza and Other Respiratory Viruses
Juliette Paireau, Cecile Durand, Sylvain C Raimbault   +2 more
exaly  

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

Vaccine
April Killikelly
exaly  

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)

Vaccine
Vaishali S Mankad, Tonya Villafana
exaly  

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis

The Lancet Regional Health Americas
Elizabeth A K Rowley, Kristin Dascomb, Jungmi Han   +2 more
exaly  

Effectiveness of nirsevimab against hospitalisation for RSV-bronchiolitis during high RSV-B circulation in the second year of nationwide implementation in France: a test-negative case-control study

Lancet Regional Health - Europe, The
Loïc De Pontual, Isabelle Hau, Celine Delestrain   +2 more
exaly  

Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database

Journal of Infection
Taito Kitano, Shinya Tsuzuki, Haruhisa Fukuda   +2 more
exaly  

Will Nirsevimab Reduce the Burden on Public Health Care?—Reply

JAMA Pediatrics
Heidi L, Moline, Meredith L, McMorrow, Fatimah S, Dawood   +2 more
openaire   +2 more sources

Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists

Hospital Pediatrics
Elena, Aragona, Neha S, Joshi, Krista L, Birnie, Poj, Lysouvakon, Rakhi Gupta, Basuray   +4 more
openaire   +2 more sources

Effectiveness of Nirsevimab in Preventing RSV Hospitalization

AAP Grand Rounds
openaire   +1 more source

RSV vaccine and nirsevimab administration errors

Reactions Weekly
openaire   +1 more source